levodopa has been researched along with Genetic Predisposition in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.89) | 18.2507 |
| 2000's | 19 (35.85) | 29.6817 |
| 2010's | 31 (58.49) | 24.3611 |
| 2020's | 2 (3.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chaurasia, RN; Dwivedi, A; Dwivedi, N; Joshi, D; Kumar, A; Mishra, VN; Mohanty, S; Pathak, A; Singh, VK | 1 |
| Funayama, M; Hattori, N; Li, Y; Nishioka, K; Peng, H; Shimizu, M; Yoshino, H | 1 |
| Guin, D; Kukreti, R; Kukreti, S; Kushwaha, SS; Mishra, MK; Rawat, C; Talwar, P | 1 |
| Antonelli, F; Cerquera, C; Ezquerra, M; Fernández-Santiago, R; Malagelada, C; Martí, MJ; Martín-Flores, N; Moreno, V | 1 |
| Cova, I; Priori, A | 1 |
| Di Battista, ME; Fattapposta, F; Lucarelli, M; Meco, G; Moret, F; Pascale, E; Pierandrei, S; Purcaro, C; Rubino, A; Vanacore, N | 1 |
| Asano, AGC; Asano, NMJ; Damasceno Dos Santos, EU; de Souza, PRE; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Dolžan, V; Flisar, D; Georgiev, D; Kojović, M; Kramberger, MG; Pirtošek, Z; Redenšek, S; Trošt, M | 1 |
| Antonini, A; Berg, D; Coon, E; Cortelli, P; Fanciulli, A; Ferreira, JJ; Freeman, R; Halliday, G; Höglinger, GU; Iodice, V; Kaufmann, H; Kaufmann, LN; Klockgether, T; Kostic, V; Krismer, F; Lang, A; Levin, J; Low, P; Mathias, C; Meissner, WG; Palma, JA; Panicker, JN; Pellecchia, MT; Poewe, W; Quinn, N; Sakakibara, R; Schmahmann, J; Scholz, SW; Seppi, K; Singer, W; Stamelou, M; Stankovic, I; Tolosa, E; Tsuji, S; Vignatelli, L; Wenning, GK | 1 |
| Jadavji, NM; Murray, LK | 1 |
| Berbellini, A; Cacchiò, G; De Michele, G; De Rosa, A; Di Marzio, F; Manca, A; Pianese, L; Ragno, M; Scarcella, M; Silvestri, S | 1 |
| Asselta, R; Cilia, R; Cohen, OS; Goldwurm, S; Greenbaum, L; Hassin-Baer, S; Inzelberg, R; Kohn, Y; Lerer, B; Lifschytz, T; Tesei, S; Yahalom, G; Zozulinsky, P | 1 |
| Bonnet, AM; Bonnet, C; Charbonnier-Beaupel, F; Cormier-Dequaire, F; Corvol, JC; Costentin, J; Devos, D; Duhamel, A; Lejeune, S; Rouaix, N; Sablonnière, B; Tahiri, K; Vidailhet, M; Zahr, N | 1 |
| Costello, D; Lynch, T; McCarthy, A; Mulroy, E; Ross, OA | 1 |
| Bjørnarå, KA; Blau, N; Koht, J; Opladen, T; Rengmark, A; Selberg, T; Tallaksen, CM; Toft, M | 1 |
| Fujimoto, KI; Funayama, M; Hatano, T; Hattori, N; Kubo, SI; Kunii, Y; Mata, IF; Mizuno, Y; Mori, A; Oji, Y; Oshima, H; Oyama, G; Shimo, Y; Waldherr, SM; Yabe, H; Yoshino, H; Zabetian, CP | 1 |
| Azulay, JP; Bardyn, T; Bordet, R; Brefel-Courbon, C; Corvol, JC; Debû, B; Defebvre, L; Delval, A; Destée, A; Devedjian, JC; Devos, D; Drapier, S; Duhamel, A; Dujardin, K; Durif, F; Eusebio, A; Faighel, M; Fraix, V; Giordana, C; Guehl, D; Houeto, JL; Labreuche, J; Lagha-Boukbiza, O; Maltête, D; Meguig, S; Moreau, C; Ory-Magne, F; Petyt, G; Rascol, O; Rouaix, N; Sablonnière, B; Saulnier, PJ; Tison, F; Tranchant, C; Vasseur, F; Vidailhet, M | 1 |
| Disse, M; Lee, PK; Reich, H; Schram, SS | 1 |
| Alaylıoğlu, M; Apaydın, H; Atasoy, İL; Bilgiç, B; Candaş, E; Dursun, E; Ertan, S; Genç, G; Gezen-Ak, D; Gündüz, A; Gürvit, H; Hanağası, H; Kızıltan, G; Yılmazer, S | 1 |
| Banerjee, M; Kishore, A; Krishnamoorthy, S; Krishnan, S; Kumar, H; Rajan, R; Sarma, G; Sarma, S | 1 |
| Altmann, V; Callegari-Jacques, SM; Hutz, MH; Rieck, M; Rieder, CRM; Schumacher-Schuh, AF | 1 |
| Bianchi, ML; Bono, G; Cantello, R; Comi, C; Cosentino, M; Ferrari, M; Magistrelli, L; Marino, F; Riboldazzi, G | 1 |
| Cho, JH; Choi, YB; Hong, KM; Kim, YS; Lee, JH; Lee, SD; Paik, MK; Shin, CH; Yang, SH | 1 |
| Hagenah, J; Klein, C; Schmidt, A; Schneider, SA | 1 |
| Guglielmi, R; Meco, G; Pascale, E; Passarelli, E; Passarelli, F; Purcaro, C; Vestri, AR | 1 |
| Charles, J; Lantuejoul, S; Leccia, MT; Leroux, D; Robert, C; Salameire, D; Templier, I | 1 |
| Chiang, TR; Ho, CS; Hu, CJ; Hung, YL; Sheu, JJ; Tseng, IJ; Yeh, CY; Yu, JM; Yuan, RY | 1 |
| Cantero, M; Cediel, R; Contreras, J; Montoliu, L; Murillo-Cuesta, S; Varela-Nieto, I; Zurita, E | 1 |
| Annesi, G; Arabia, G; Barone, P; Cozzolino, A; De Mari, M; Epifanio, A; Gallerini, S; Lamberti, P; Marconi, R; Morgante, L; Nicoletti, A; Nicoletti, G; Pugliese, P; Quattrone, A; Torchia, G; Zappia, M | 1 |
| Belcastro, V; Calabresi, P; Castrioto, A; Gorgone, G; Ientile, R; Menichetti, C; Pierguidi, L; Pisani, F; Rossi, A; Tambasco, N | 1 |
| Breit, S; Freudenstein, D; Gasser, T; Krüger, R; Leitner, P; Nägele, T; Schmid-Bielenberg, D; Wächter, T; Weiss, D | 1 |
| Cho, J; Jeon, BS; Lee, EK; Lee, JY; Park, SS | 1 |
| Aharon-Peretz, J; Cohen, OS; Dagan, E; Djaldetti, R; Ephraty, L; Fixler Mehr, T; Friedman, E; Gershoni-Baruch, R; Hassin-Baer, S; Inzelberg, L; Inzelberg, R; Kaplan, N; Kozlova, E; Mory, A; Nitsan, Z; Schechtman, E; Schlesinger, I; Tunkel, O | 1 |
| Biswas, A; Das, SK; Misra, AK; Naiya, T; Ray, J; Ray, K | 1 |
| Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G | 1 |
| Al Hadithy, AF; Alifirova, VM; Brouwers, JR; Fedorenko, OY; Freidin, MB; Govorin, NV; Ivanova, SA; Loonen, AJ; Pechlivanoglou, P; Rudikov, EV; Semke, AV; Sorokina, VA; Wilffert, B; Zhukova, IA | 1 |
| Altmann, V; Callegari-Jacques, SM; Fagundes, PT; Francisconi, CL; Hutz, MH; Monte, TL; Rieck, M; Rieder, CR; Schumacher-Schuh, AF | 1 |
| Chien, WL; Fu, WM; Hung, SY; Kang, KH; Lee, MJ; Lee, TR; Wu, RM | 1 |
| Bird, T; Farrer, M; Gancher, S; Gwinn-Hardy, K; Hardy, J; Hussey, J; Lockhart, P; McNeal, MG; Nutt, J; Payami, H; Seltzer, WK; Singleton, AA; Singleton, AB | 1 |
| Bhatia, KP; Critchley, P; Graham, E; Khan, NL; Lees, AJ; Quinn, N; Schrag, AE; Wood, NW | 1 |
| Bembi, B; LaMarca, ME; Orvisky, E; Rosenbaum, H; Schiffmann, R; Sidransky, E; Stubblefield, B; Tayebi, N; Walker, J; Wong, K | 1 |
| Berendse, HW; Booij, J; Farrer, MJ; Hulihan, MM; Kachergus, JM; Krygowska-Wajs, A; Searcy, JA; Wolters, ECh; Wszolek, ZK | 1 |
| Annesi, F; Annesi, G; Arabia, G; Carrideo, S; Cirò-Candiano, IC; Civitelli, D; De Marco, EV; Gambardella, A; Messina, D; Nicoletti, G; Pugliese, P; Quattrone, A; Spadafora, P; Tarantino, P; Zappia, M | 1 |
| Albanese, A; Bellacchio, E; Dallapiccola, B; Elia, AE; Romito, LM; Valente, EM | 1 |
| Hattori, N; Inzelberg, R; Mizuno, Y | 1 |
| Ahmed, M; Bohlega, S; Carroll, P; Chishti, MA; Loualich, A; Rogaeva, E; Sato, C; St George-Hyslop, P; Westaway, D | 1 |
| Harn, HJ; Lin, JJ; Lin, SZ; Liu, JT; Yueh, KC | 1 |
| Clement, F; Coubes, P; Defebvre, L; Destee, A; Devos, D; Moreau, C | 1 |
| Concolino, D; Moricca, MT; Muzzi, G; Pascale, MG; Rapsomaniki, M; Strisciuglio, P | 1 |
| Aguglia, U; Andreoli, V; Annesi, G; Branca, D; Cittadella, R; Civitelli, D; Gambardella, A; Montesanti, R; Nicoletti, G; Oliveri, RL; Pasqua, AA; Quattrone, A; Spadafora, P; Zappia, M | 1 |
| Aitchison, KJ; Arranz, MJ; Forsyth, J; Graham, JM; Grünewald, RA; Li, T; Makoff, AJ; Shaikh, S | 1 |
| Botha, R; Chen, S; Reuhl, K; Ryan, K; Wei, J; Zhu, H | 1 |
| Allen, FH; Booze, MW; Colcher, A; Gibson, RA; Goetz, CG; Haines, JL; Hiner, BC; Hubble, JP; Jankovic, J; Koller, WC; Laing, NG; Lyons, K; Mastaglia, F; Masterman, D; Middleton, LT; Nance, MA; Ondo, WG; Pahwa, R; Pericak-Vance, MA; Rampersaud, E; Ribble, RC; Roses, AD; Scott, BL; Scott, WK; Slotterbeck, B; Small, GW; Stajich, JM; Stern, MB; Vance, JM; Watts, RL; West, SG | 1 |
6 review(s) available for levodopa and Genetic Predisposition
| Article | Year |
|---|---|
Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
Topics: Catechol O-Methyltransferase; Dyskinesias; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide | 2023 |
A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease.
Topics: Genetic Predisposition to Disease; Humans; Levodopa; Parkinson Disease; Protein Interaction Maps | 2017 |
Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Topics: alpha-Synuclein; Biomarkers; Brain; Cognition Disorders; Constipation; Depression; Early Diagnosis; Genetic Predisposition to Disease; Humans; Inflammation; Levodopa; Metabolomics; Microbiota; Movement Disorders; Neuroimaging; Olfaction Disorders; Parkinson Disease; REM Sleep Behavior Disorder; Symptom Assessment; Vision Disorders | 2018 |
The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms.
Topics: Animals; Diet; Folic Acid; Genetic Predisposition to Disease; Homocysteine; Humans; Levodopa; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Nutritional Status; One-Carbon Group Transferases; Parkinson Disease; Polymorphism, Genetic; Vitamin B Complex | 2019 |
A Review of the Association Between Parkinson Disease and Malignant Melanoma.
Topics: Antiparkinson Agents; Environment; Genetic Predisposition to Disease; Humans; Levodopa; Melanoma; Parkinson Disease; Risk Factors; Skin Neoplasms; Skin Pigmentation | 2016 |
[Dystonia].
Topics: Cholinergic Antagonists; Deep Brain Stimulation; Dystonia; Genetic Predisposition to Disease; Humans; Levodopa; Molecular Chaperones | 2008 |
4 trial(s) available for levodopa and Genetic Predisposition
| Article | Year |
|---|---|
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Resistance; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; ROC Curve | 2014 |
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Topics: Aged; Catechol O-Methyltransferase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Middle Aged; Parkinson Disease; Polymorphism, Genetic | 2015 |
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cohort Studies; DNA Mutational Analysis; DNA Repeat Expansion; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Humans; Levodopa; Male; Multivariate Analysis; Parkinson Disease; Polymorphism, Genetic; Predictive Value of Tests; Receptors, Dopamine D2; Sex Characteristics | 2005 |
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
Topics: Alleles; Antiparkinson Agents; Dopamine Agonists; Female; Gene Frequency; Genetic Linkage; Genetic Predisposition to Disease; Genotype; Hallucinations; Haplotypes; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2000 |
43 other study(ies) available for levodopa and Genetic Predisposition
| Article | Year |
|---|---|
Analysis of LIN28A variants in patients with Parkinson's disease.
Topics: Genetic Predisposition to Disease; Humans; Levodopa; Loss of Heterozygosity; Middle Aged; Parkinson Disease | 2023 |
MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
Topics: Alleles; Dyskinesia, Drug-Induced; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide; Retrospective Studies; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Alleles; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Italy; Levodopa; Male; Minisatellite Repeats; Parkinson Disease; Polymorphism, Genetic; Prevalence | 2019 |
Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
Topics: Aged; Alleles; Antiparkinson Agents; Female; Genetic Predisposition to Disease; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide | 2019 |
Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Genetic Predisposition to Disease; Genotype; Humans; Inflammation; Levodopa; Male; Oxidative Stress; Parkinson Disease; Polymorphism, Single Nucleotide | 2019 |
A critique of the second consensus criteria for multiple system atrophy.
Topics: Consensus; Genetic Predisposition to Disease; Humans; Levodopa; Multiple System Atrophy; Treatment Outcome | 2019 |
Parkinsonism is a late, not rare, feature of CADASIL: a study on Italian patients carrying the R1006C mutation.
Topics: Aged; Brain; CADASIL; Exons; Female; Genetic Predisposition to Disease; Humans; Italy; Leukoencephalopathies; Levodopa; Magnetic Resonance Imaging; Male; Mutation; Parkinsonian Disorders; Receptor, Notch3; Receptors, Notch; Tomography, Emission-Computed, Single-Photon | 2013 |
Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.
Topics: Aged; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Humans; Israel; Italy; Jews; Levodopa; Male; Middle Aged; Polymorphism, Single Nucleotide | 2013 |
Asymmetrical leg atrophy in levodopa-responsive dystonia due to a novel GTP cyclohydrolase mutation.
Topics: Adult; Atrophy; Dystonia; Genetic Predisposition to Disease; Genetic Testing; GTP Cyclohydrolase; Humans; Leg; Levodopa; Male; Mutation | 2014 |
Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene.
Topics: Adolescent; Alcohol Oxidoreductases; Child; Dystonic Disorders; Female; Genetic Predisposition to Disease; Humans; Levodopa; Mutation; Pedigree; Pterins | 2014 |
Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
Topics: Adult; Aged; Asian People; Cohort Studies; Exons; Female; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Pedigree; Protein Serine-Threonine Kinases; Sequence Analysis, DNA | 2014 |
GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Alleles; Antiparkinson Agents; Calcifediol; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Levodopa; Luminescent Measurements; Male; Middle Aged; Parkinson Disease; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Risk; RNA, Messenger; Turkey; Vitamin D-Binding Protein; Young Adult | 2017 |
Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.
Topics: Adult; Aged; Asian People; Case-Control Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Dopamine D3 | 2016 |
Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
Topics: Aged; Female; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2018 |
Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
Topics: Aged; Alleles; Animals; Disease Progression; Dyskinesias; Female; Genetic Predisposition to Disease; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptors, Dopamine | 2017 |
Predisposition of genetic disease by modestly decreased expression of GCH1 mutant allele.
Topics: Child; Clubfoot; Dopamine; Dystonic Disorders; Genes, Recessive; Genetic Predisposition to Disease; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation, Missense; Pedigree; Polymorphism, Genetic | 2008 |
Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects.
Topics: Aged; Antiparkinson Agents; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Statistics, Nonparametric | 2009 |
Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease.
Topics: DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Levodopa; Male; Melanoma; Middle Aged; Parkinson Disease; Skin Neoplasms; Ultraviolet Rays | 2009 |
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Topics: Age Distribution; Aged; Aged, 80 and over; Amino Acid Substitution; Antiparkinson Agents; Base Sequence; Biomarkers; DNA Mutational Analysis; Female; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Dehydrogenase (NAD+); Parkinson Disease; Polymorphism, Genetic; Sex Distribution | 2009 |
Melanin precursors prevent premature age-related and noise-induced hearing loss in albino mice.
Topics: Aging; Aging, Premature; Albinism; Albinism, Oculocutaneous; Animals; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Gene Expression Regulation, Enzymologic; Genetic Predisposition to Disease; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Levodopa; Melanins; Mice; Mice, Transgenic; Monophenol Monooxygenase; Tyrosine 3-Monooxygenase | 2010 |
The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Dopamine Agonists; Dyskinesias; Environment; Female; Genetic Predisposition to Disease; Geography; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Sequence Analysis, DNA; Severity of Illness Index; Spouses; Surveys and Questionnaires | 2010 |
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients.
Topics: Aged; Cross-Sectional Studies; Dopamine Agents; Female; Genetic Predisposition to Disease; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Secondary Prevention; Treatment Outcome; Vitamin B 12 | 2010 |
Effective long-term subthalamic stimulation in PARK8 positive Parkinson's disease.
Topics: DNA Mutational Analysis; Electric Stimulation Therapy; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation, Missense; Parkinson Disease; Predictive Value of Tests; Protein Serine-Threonine Kinases; Subthalamic Nucleus; Time; Treatment Outcome | 2010 |
Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Probability; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Serotonin Plasma Membrane Transport Proteins; Young Adult | 2011 |
The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Ethnicity; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Jews; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Logistic Models; Male; Middle Aged; Mutation; Neoplasms; Parkinson Disease; Protein Serine-Threonine Kinases; Sex Factors; Survival Analysis | 2012 |
Occurrence of GCH1 gene mutations in a group of Indian dystonia patients.
Topics: Adult; Asian People; DNA Mutational Analysis; Dopamine Agents; Dystonia; Family Health; Female; Genetic Predisposition to Disease; GTP Cyclohydrolase; Humans; India; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease | 2012 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Predisposition to Disease; Glycine; Humans; Israel; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Longitudinal Studies; Male; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Retrospective Studies; Serine; Statistics, Nonparametric; Young Adult | 2012 |
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.
Topics: Age of Onset; Alleles; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Gene Expression; Genetic Predisposition to Disease; Genotype; Humans; Huntington Disease; Levodopa; Long-Term Care; Motor Cortex; Movement Disorders; Polymorphism, Single Nucleotide; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2012 |
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Receptors, Dopamine D2 | 2012 |
Increase of oxidative stress by a novel PINK1 mutation, P209A.
Topics: Age of Onset; Cell Line; Female; Genetic Predisposition to Disease; Heme Oxygenase-1; Heterozygote; Humans; Levodopa; Male; Mutation; Oxidative Stress; Parkinson Disease; Phosphorylation; Protein Kinases; Superoxide Dismutase | 2013 |
SCA2 may present as levodopa-responsive parkinsonism.
Topics: Adult; Aged; Alleles; Anticipation, Genetic; Antiparkinson Agents; Ataxins; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Pedigree; Phenotype; Proteins; Treatment Outcome; Trinucleotide Repeats | 2003 |
Parkin disease: a phenotypic study of a large case series.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dystonia; Female; Genetic Predisposition to Disease; Humans; Levodopa; Ligases; Male; Mental Disorders; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; Polymerase Chain Reaction; Ubiquitin-Protein Ligases | 2003 |
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
Topics: Adult; Blotting, Southern; Brain; Deoxyribonucleases, Type II Site-Specific; Female; Gaucher Disease; Genetic Predisposition to Disease; Glucosylceramidase; Homozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Psychosine; Sphingosine | 2003 |
Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Chromosome Mapping; Corpus Striatum; DNA Mutational Analysis; Dopamine Plasma Membrane Transport Proteins; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Inheritance Patterns; Levodopa; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Pedigree; Poland; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2005 |
The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease.
Topics: Age of Onset; Brain; Diagnosis, Differential; Dopamine Agents; Energy Metabolism; Genetic Predisposition to Disease; Humans; Italy; Levodopa; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Mutation; Parkinson Disease; Parkinsonian Disorders; Phenotype; Protein Kinases; Shy-Drager Syndrome; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.
Topics: Adult; Age of Onset; Brain; Dopamine; Ethnicity; Female; Genetic Carrier Screening; Genetic Predisposition to Disease; Heterozygote; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Tremor; Ubiquitin-Protein Ligases | 2005 |
T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease.
Topics: Adolescent; Adult; Age of Onset; Amino Acid Substitution; Child; Child, Preschool; Consanguinity; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homozygote; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree; Protein Kinases; Saudi Arabia; Treatment Outcome | 2006 |
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Homozygote; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Predictive Value of Tests; Psychoses, Substance-Induced; Risk Factors | 2007 |
Neurodegeneration with brain iron accumulation: clinical, radiographic and genetic heterogeneity and corresponding therapeutic options.
Topics: Adolescent; Brain; Brain Diseases, Metabolic; Diagnosis, Differential; DNA Mutational Analysis; Dystonia; Female; Genetic Predisposition to Disease; Humans; Iron; Iron Metabolism Disorders; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Pantothenate Kinase-Associated Neurodegeneration; Phosphotransferases (Alcohol Group Acceptor); Treatment Outcome | 2007 |
Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients.
Topics: 5-Hydroxytryptophan; Aromatic Amino Acid Decarboxylase Inhibitors; Biomarkers; Carbidopa; Child, Preschool; Dietary Proteins; Dihydropteridine Reductase; Dopa Decarboxylase; Dopamine Agents; Drug Monitoring; Drug Therapy, Combination; Enzyme Inhibitors; Genetic Predisposition to Disease; Humans; Infant; Infant, Newborn; Italy; Levodopa; Monoamine Oxidase Inhibitors; Mutation; Neonatal Screening; Neurologic Examination; Phenotype; Phenylketonurias; Prolactin; Selegiline; Time Factors; Treatment Outcome | 2008 |
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
Topics: Adult; Aged; Alleles; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Dyskinesias; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Tandem Repeat Sequences | 1999 |
Development of early melanocytic lesions in transgenic mice predisposed to melanoma.
Topics: Animals; Animals, Newborn; Anus Neoplasms; Ear Neoplasms; Eyelid Neoplasms; Genetic Predisposition to Disease; Levodopa; Melanocytes; Melanoma, Experimental; Mice; Mice, Transgenic; Neural Crest; Skin Neoplasms | 2000 |
Complete genomic screen in Parkinson disease: evidence for multiple genes.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Drug Resistance; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Ligases; Lod Score; Microsatellite Repeats; Middle Aged; Parkinson Disease; Risk Factors; Ubiquitin-Protein Ligases | 2001 |